The KCNH5 antibody targets the potassium voltage-gated channel subfamily H member 5 (KCNH5), also known as Ether-à-go-go-related gene 2 (ERG2). KCNH5 belongs to the EAG family of voltage-gated potassium channels, which regulate neuronal excitability, cardiac repolarization, and cellular proliferation. This transmembrane protein contains six membrane-spanning domains and a cyclic nucleotide-binding homology domain, playing roles in action potential repolarization and intracellular signaling. KCNH5 is predominantly expressed in the brain, particularly in the hippocampus, cortex, and cerebellum, and is implicated in neurological disorders such as epilepsy, developmental delay, and migraines. Dysregulation of KCNH5 has also been linked to cancer, including glioblastoma and neuroblastoma, where its overexpression may promote tumor growth and chemoresistance.
KCNH5 antibodies are essential tools for studying the protein's expression, localization, and function in physiological and pathological contexts. They are widely used in techniques like Western blotting, immunohistochemistry, and immunofluorescence to investigate KCNH5's role in ion channel dynamics, neuronal signaling, and disease mechanisms. Recent studies highlight its potential as a therapeutic target or biomarker, particularly in drug-resistant cancers. Researchers often validate these antibodies using knockout cell lines or tissues to ensure specificity. As KCNH5 research expands, its antibodies remain critical for unraveling its contributions to cellular excitability, cancer progression, and neurological disorders.